Oncology – Page 22

Rising Incidence of Breast Cancer Among Young Women: Trends and Implications from 1990 to 2023

By MedXY 10/09/2025

Early-onset breast cancer incidence in France has steadily increased over the past three decades, mirroring trends in other Western countries. Shifts in hormonal and lifestyle factors may contribute, highlighting the need for adapted prevention and screening strategies.

Family Medicine & Nutrition news Oncology

Decoding the Rise in Early-Onset Cancer: Implications for Primary Care and Screening Strategies

By MedXY 10/09/2025

Rising early-onset cancer incidence appears driven largely by increased diagnostic scrutiny and overdiagnosis rather than a true surge in disease, altering screening and management approaches in primary care.

Gastroenterology news Oncology

Menopausal Hormone Therapy and Reduced Risk of Upper Gastrointestinal Cancers: Insights From a Large Nordic Population Study

By MedXY 10/08/2025

A large Nordic study finds menopausal hormone therapy reduces the risk of esophageal and gastric cancers by up to 30%, especially with combined estrogen-progestin systemic formulations.

news Oncology Urology

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

By MedXY 10/05/2025

Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment access and awareness.

news OB/GYN & Women's Health Oncology Radiology Specialties

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer

By MedXY 10/04/2025

This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection and poorer prognosis.

General Surgery news Oncology

Defining Cure in Stage II-III Colon Cancer: Insights from a Pooled Analysis of 15 Randomized Trials

By MedXY 10/04/2025

A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.

news Oncology Otorhinolaryngology

Evaluating Partial versus Whole Laryngeal Radiotherapy in Early-Stage Laryngeal Carcinoma: A Retrospective Cohort Analysis

By MedXY 10/04/2025

This study compares partial laryngeal radiotherapy (PLRT) and whole laryngeal radiotherapy (WLRT) in T1-2N0M0/Tis laryngeal carcinoma, demonstrating comparable locoregional control but less acute toxicity with PLRT, though longer follow-up is needed.

news Oncology Radiology Specialties Urology

PSMA PET-Guided Intensification of Salvage Radiotherapy Enhances Outcomes Post-Radical Prostatectomy: Insights from a Phase 2 RCT

By MedXY 10/04/2025

A phase 2 randomized trial demonstrates that PSMA-PET-guided intensification of salvage radiotherapy after radical prostatectomy significantly improves failure-free survival without added toxicity.

Clinical Updates news Oncology Specialties

Evaluating the Addition of Polymeric Micellar Paclitaxel to Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: Insights from a Phase 3 Randomized Clinical Trial

By MedXY 10/01/2025

A South Korean phase 3 trial found that adding polymeric micellar paclitaxel to gemcitabine and cisplatin did not improve survival for advanced biliary tract cancer, highlighting the challenges of intensified chemotherapy regimens.

Clinical Updates news Oncology Specialties

Bridging the Gap: Overcoming Barriers to Timely Melanoma Diagnosis and Treatment in Latino Patients

By MedXY 10/01/2025

This article explores the facilitators and barriers Latino patients face in timely melanoma diagnosis and treatment, highlighting health insurance, linguistic challenges, and patient advocacy as key factors affecting outcomes.

Clinical Updates Oncology Specialties

Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics

By MedXY 09/30/2025

Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these microbes to improve treatment efficacy and overcome resistance.

Clinical Updates Oncology

Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis

By MedXY 09/30/2025

Low-molecular-weight dextran sulfate sodium (LMW-DSS), a new heparanase inhibitor, effectively prevents breast cancer metastasis in mice by inhibiting cancer cell migration and angiogenesis, offering a promising therapeutic approach with minimal bleeding risk.

Clinical Updates Oncology Specialties

Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment

By MedXY 09/29/2025

A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.

OB/GYN & Women's Health Oncology Specialties

Seventeen Years On: Robust Population-Level Effectiveness and Herd Protection from HPV Vaccination in High-Risk Young Women

By MedXY 09/29/2025

Seventeen years after HPV vaccine introduction, substantial reductions in vaccine-type HPV prevalence confirm strong effectiveness and herd protection among vaccinated and unvaccinated sexually experienced adolescent girls and young women at high risk for HPV.

OB/GYN & Women's Health Oncology Specialties

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost

By MedXY 09/28/2025

Breast cancer screening among older US women shows stable use but rising costs driven by low-value technologies; optimizing screening strategies could enhance value and reduce expenditure.

news Oncology Specialties

Painful Sunburns and Their Link to Cutaneous Squamous Cell Carcinoma: Insights from a Comprehensive Meta-Analysis

By MedXY 09/28/2025

A meta-analysis of over 320,000 participants confirms that painful, blistering sunburns, especially in childhood, significantly increase the risk of cutaneous squamous cell carcinoma (cSCC).

AI news Oncology Radiology Specialties

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY 09/27/2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy.

Family Medicine & Nutrition Oncology Specialties

Vitamin B12 Supplementation Halves Risk of Chemotherapy-Induced Hand-Foot Syndrome in Early Breast Cancer Patients

By MedXY 09/25/2025

A phase 3 trial finds high-dose oral vitamin B12 significantly reduces moderate-to-severe hand-foot syndrome in women receiving capecitabine chemotherapy, without increasing toxicity, offering a safe and convenient preventive option.

Clinical Updates news OB/GYN & Women's Health Oncology

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

By MedXY 09/25/2025

The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.

Clinical Updates news Oncology

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study

By MedXY 09/25/2025

This study suggests adjuvant immunotherapy may not enhance survival after neoadjuvant chemoimmunotherapy and surgery in stage III NSCLC, with three cycles of neoadjuvant immunotherapy appearing optimal.